Cullinan Therapeutics Inc’s recently made public that its Chief Business Officer Savill Corrine unloaded Company’s shares for reported $0.65 million on Feb 01 ’24. In the deal valued at $16.18 per share,40,000 shares were sold. As a result of this transaction, Savill Corrine now holds 165,990 shares worth roughly $4.71 million.
Then, Savill Corrine sold 40,000 shares, generating $563,600 in total proceeds. Upon selling the shares at $14.09, the Chief Business Officer now owns 165,990 shares.
Before that, Savill Corrine sold 21,316 shares. Cullinan Therapeutics Inc shares valued at $265,597 were divested by the Chief Business Officer at a price of $12.46 per share. As a result of the transaction, Savill Corrine now holds 165,990 shares, worth roughly $4.71 million.
Stifel initiated its Cullinan Therapeutics Inc [CGEM] rating to a Buy in a research note published on May 01, 2024; the price target was $40. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in mid April with a ‘”an Outperform”‘ rating. Wedbush began covering CGEM with “an Outperform” recommendation on February 15, 2024. TD Cowen started covering the stock on June 15, 2023. It rated CGEM as “an Outperform”.
Price Performance Review of CGEM
On Monday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock jump 0.18% to $28.40. Over the last five days, the stock has gained 4.72%. Cullinan Therapeutics Inc shares have risen nearly 178.70% since the year began. Nevertheless, the stocks have risen 195.83% over the past one year. While a 52-week high of $29.25 was reached on 05/03/24, a 52-week low of $7.64 was recorded on 01/11/24. SMA at 50 days reached $18.54, while 200 days put it at $12.67. A total of 0.77 million shares were traded, compared to the trading of 0.99 million shares in the previous session.
Levels Of Support And Resistance For CGEM Stock
The 24-hour chart illustrates a support level at 27.54, which if violated will result in even more drops to 26.69. On the upside, there is a resistance level at 29.05. A further resistance level may holdings at 29.71. The Relative Strength Index (RSI) on the 14-day chart is 80.03, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 5.69, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 6.05%. Stochastics %K at 92.16% indicates the stock is a selling.
The most recent change occurred on November 21, 2022 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
